Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew P McGovern

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Diabetologia|June 5, 2024
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approachLaura M Güdemann, Katie G Young, Nicholas J M Thomas, et al.
The Lancet. Primary Care|May 11, 2026
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care dataThijs T Jansz, Andrew P McGovern, Katherine G Young, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|May 20, 2026
Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation StudyKatherine G Young, Andrew P McGovern, Rhian Hopkins, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitorsKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
The Lancet. Digital Health|November 25, 2022
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort studyJohn M Dennis, Katherine G Young, Andrew P McGovern, et al.
Communications Medicine|October 4, 2023
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic reviewKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
Diabetologia|February 22, 2024
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesPedro Cardoso, Katie G Young, Anand T N Nair, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Diabetologia|June 5, 2024
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approachLaura M Güdemann, Katie G Young, Nicholas J M Thomas, et al.
The Lancet. Primary Care|May 11, 2026
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care dataThijs T Jansz, Andrew P McGovern, Katherine G Young, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|May 20, 2026
Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation StudyKatherine G Young, Andrew P McGovern, Rhian Hopkins, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitorsKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
The Lancet. Digital Health|November 25, 2022
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort studyJohn M Dennis, Katherine G Young, Andrew P McGovern, et al.
Communications Medicine|October 4, 2023
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic reviewKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
Diabetologia|February 22, 2024
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesPedro Cardoso, Katie G Young, Anand T N Nair, et al.
Pageof 4